Answer
Breastfeeding should be discontinued throughout treatment with VITRAKVI (larotrectinib sulfate) and for 3 days after the final dose.
Sources for this answer
- Vitrakvi 25 mg hard capsulesBayer plc · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 14Document updated
Sources checked